Molecular Infectious Disease Testing Market

The molecular infectious disease testing market is expected to grow from USD 11.30 billion in 2026 to USD 19.01 billion by 2031. This growth is driven by the increasing burden of infections such as HIV, HPV, hepatitis, and chlamydia/gonorrhea (CT/NG). Accurate and rapid diagnoses are essential for controlling outbreaks and improving treatment outcomes. Furthermore, there is a heightened focus on research and development in molecular diagnostics, which will support demand for advanced techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). These technologies will facilitate faster, more accurate, and multiplexed molecular diagnostic tests in the future. Additionally, funding for these advancements is becoming more accessible across the public and private sectors, owing to government efforts to enhance diagnostic capabilities. Consequently, the market is anticipated to witness significant innovation in advanced molecular diagnostic technologies in the near future.

In December 2024, bioMérieux (France) announced that its BIOFIRE FILMARRAY Tropical Fever (TF) Panel received Special 510(k) clearance from the US Food and Drug Administration. This innovative PCR testing solution is designed to quickly and accurately identify pathogens in patients with unexplained fever, ultimately optimizing treatment.

To know about the assumptions considered for the study download the pdf brochure

In September 2024, F. Hoffmann-La Roche Ltd. (Switzerland) launched the cobas Respiratory flex test, the first test to use Roche's novel, proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology employs multiplex polymerase chain reaction (PCR) testing, combined with color, temperature, and data processing, to identify up to 15 pathogens in a single PCR test.

The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These market players have adopted several strategies, including advanced product development, partnerships, expansions, and acquisitions, to strengthen their market positions. These organic and inorganic strategies have enabled market players to expand across geographies by providing advanced molecular infectious disease tests.

Danaher (US) emerged as the leading company in the molecular infectious disease testing market in 2025. Establishing itself as a leader in the US market provides the company with an advantageous platform to access emerging markets and enhance its global presence. Additionally, Danaher is expected to innovate and develop products that meet customer needs worldwide, enabling it to further capitalize on its market leadership. The company has implemented strategic actions focused on organic growth, including the launch of new products and obtaining necessary regulatory approvals. For example, in March 2024, the US FDA approved the Xpert Xpress GBS test. This approach has helped Danaher maintain its position as a market leader in molecular infectious disease testing.

F. Hoffmann-La Roche Ltd. (Switzerland) is a significant player in the molecular infectious disease testing industry. Its diverse product range and global operations have enabled the company to maintain a competitive edge. F. Hoffmann-La Roche Ltd has established a highly effective distribution network, both direct and indirect, enabling it to manage fluctuations in demand across various markets efficiently. The company's focus on both organic and inorganic growth strategies strengthens its position in the marketplace. For example, in September 2024, F. Hoffmann-La Roche Ltd. introduced the cobas Respiratory Flex Test, the first test developed by Roche to use its unique, proprietary TAGS (Temperature-activated Generation of Signal) technology. This TAGS technology can detect up to 15 pathogens in a single PCR test through multiplex polymerase chain reaction, employing color, temperature, and data-processing techniques.

Market Ranking

Danaher Corporation has established itself as a market leader in molecular infectious disease testing due to its impressive range of molecular diagnostics platforms and innovations from its subsidiaries. F. Hoffmann-La Roche Ltd. holds a significant share of the market due to its extensive range of PCR-based tests and automated diagnostic instruments. The company boasts an effective global distribution channel and actively pursues growth-oriented strategies.

bioMérieux has emerged as a dominant player in the industry, benefiting from its superior syndromic testing capabilities and established global presence. The company continually invests in research and development to enhance its offerings. Similarly, Hologic, Inc. makes a significant contribution to the molecular infectious disease testing market with its high-performance molecular testing systems.

Abbott Laboratories is also an important player in this market, providing reliable molecular testing systems and point-of-care solutions for diagnosing infectious diseases.

Related Reports:

Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]